Industry Program

Objectives: Cytokine-targeted therapies continue to improve the treatment landscape of rheumatic and autoinflammatory diseases. This symposium will focus on the evolving role of IL-1 and IL-6 pathway targeting, highlighting recent clinical evidence and practical experience with olokizumab and goflikicept across adult and pediatric inflammatory disorders. Experts will discuss current challenges in disease management, emerging therapeutic approaches, and the future potential of targeted cytokine inhibition in improving long-term patient care. Agenda – Friday 30 October Chairperson: A/Prof Jose Paulo Lorenzo and

Crossroads of Inflammation: What Advances in PsA/SpA Mean for Clinical Practice Synopsis: The APEX study evaluated guselkumab in adults with active, erosive psoriatic arthritis and demonstrated meaningful clinical and radiographic benefits through Week 48. Participants met predefined activity and erosive criteria and were randomized to two guselkumab dosing regimens or placebo with crossover at Week 24. By Week 48, both guselkumab schedules showed sustained improvements in ACR20 and ACR50 responses, along with continued suppression of radiographic progression, while patients switched

Title coming soon Objectives: Information coming soon.

Tacrolimus strategy for Autoimmune real-world in Rheumatic Disease Objectives: Information coming soon.

The significance of IL-6 signal blocking in autoimmune diseases including RA Objectives: At this sponsored symposium, lectures will be provided by Japanese and Korean opinion leaders on the importance of blocking IL-6 signaling in autoimmune diseases, particularly RA. Agenda – Friday 30 October Chairpersons: Prof Tsutomu Takeuchi and Prof Sang-heon Lee 1730-1755 Current Landscape and Clinical Experience of IL-6 Receptor Inhibition in Korean RA Patients Prof Chan-bum Choi 1755-1820 The Efficacy of IL-6 Receptor Blocking on RA and Large Vessel

From Evidence to Confidence: Real-world Clinical Experience with Biosimilars in Europe Objectives: Norway was one of the first countries to implement widespread biosimilar use, led by pioneering research such as the NOR-SWITCH study. This session features Professor Tore K. Kvien, who will share his extensive, decade-long experience with biosimilars in clinical practice. The discussion will move beyond theoretical benefits to focus on long-term real-world data, the evolution of clinician and patient perspectives, and the practical “Experience” that has shaped current